GlassScriptPhysician profile
Carol A Mckenzie
NPI 1497869366
$2,999.80
in general payments reported to CMS, 2019-2025
25 companies · $537 in 2025
The $537 reported for 2025 was more than what 76% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $145 · 2021: $350 · 2022: $392 · 2023: $235 · 2024: $517 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,288.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $635.09 | 2022-2025 | |
| Abbvie INC. | $524.63 | 2019-2025 | |
| Amgen INC. | $424.89 | 2019-2022 | |
| Astellas Pharma US INC | $337.65 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $216.64 | 2019-2021 | |
| Agile Therapeutics, INC. | $92.00 | 2021-2024 | Twirla |
| Intuitive Surgical, INC. | $90.32 | 2022 | |
| Myovant Sciences INC. | $85.70 | 2022 | |
| Pfizer INC. | $75.48 | 2019 | |
| Hologic Sales and Service, LLC | $64.90 | 2021-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Sumitomo Pharma America, INC. | $63.83 | 2024-2025 | Myfembree |
| Millicent US INC | $61.07 | 2019-2025 | Intrarosa, Femlyv, Femring |
| Coopersurgical, INC. | $54.17 | 2020-2023 | Paragard T 380a |
| Boston Scientific Corporation | $52.69 | 2023 | Resolution 360 Clip |
| Exeltis, USA INC. | $42.13 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $38.81 | 2019-2021 | |
| Lilly USA, LLC | $28.93 | 2025 | Zepbound |
| Duchesnay USA Incorporated | $22.20 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.97 | 2019 | |
| Currax Pharmaceuticals LLC | $13.84 | 2022 | |
| Allergan, INC. | $13.31 | 2019 | |
| Virtus Pharmaceuticals LLC | $13.31 | 2021 | |
| Avion Pharmaceuticals | $13.18 | 2021 | |
| Roche Diagnostics Corporation | $12.46 | 2020 | |
| Channel Medsystems, INC. | $4.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.